Blood disorders
Lymphoma in Zhengzhou
郑州 淋巴瘤
4 hospitals in Zhengzhou
Order: papers led on lymphoma, 2021–2025, then A–Z. Research activity, not a rating of care.
Only hospitals listed for lymphoma: those with enough papers or registered trials on it in the records this site uses. Other hospitals in Zhengzhou may also treat it. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first.
- 85 papers led
- 27 papers led
- 13 papers ledNo open trial led
- 0 papers ledNo open trial led
Lymphoma in every city Zhengzhou on the disease page, with the national map
open trials on lymphoma with a hospital in Zhengzhou
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with a listed hospital in Zhengzhou as lead sponsor or study site. 16 of them are led by a hospital in Zhengzhou. Check the registry for the current status. Whether someone can take part is decided by the study team.
Only trials registered on ClinicalTrials.gov are counted. Trials registered only in China’s own registry (ChiCTR) are not.
- RecruitingA Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Phase
- Phase 4
- Started
- 2026-03
- Posted
- Registry
- NCT07218341
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Lanzhou, Nanchang, Shanghai, Tianjin, Urumqi, Xuzhou, Zhengzhou
- RecruitingA Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
- Phase
- Phase 3
- Started
- 2026-03
- Posted
- Registry
- NCT07409428
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 42 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Quanzhou, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xuzhou, Zhengzhou
- RecruitingA Study of APG-3288 in Relapsed/Refractory Blood Cancers
- Phase
- Phase 1
- Started
- 2026-03
- Posted
- Registry
- NCT07424833
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou
- RecruitingExploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07441993
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 11 listed hospitals as study sitesBeijing, Changchun, Changsha, Guangzhou, Jinan, Nanchang, Nantong, Tianjin, Wuhan, Zhengzhou
- RecruitingAssessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)
- Phase
- Phase 1/Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07496229
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesChengdu, Chongqing, Fuzhou, Nanjing, Nanning, Shanghai, Taiyuan, Wenzhou, Wuhan, Zhengzhou
- RecruitingA Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
- Phase
- Phase 1/Phase 2
- Started
- 2026-05
- Posted
- Registry
- NCT07519772
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Shanghai, Zhengzhou
- RecruitingA Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
- Phase
- Phase 3
- Started
- 2025-03
- Posted
- Registry
- NCT06742996
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Linyi, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Wenzhou, Wuhan, Xuzhou, Zhengzhou
- RecruitingClinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT06829771
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Bengbu, Changchun, Fuzhou, Guangzhou, Harbin, Lanzhou, Luzhou, Quanzhou, Shanghai, Taiyuan, Tianjin, Wuhan, Xi'an, Xuzhou, Yantai, Zhengzhou
- RecruitingClinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma
- Phase
- Phase 2
- Started
- 2025-03
- Posted
- Registry
- NCT06854445
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesChangsha, Dalian, Hangzhou, Harbin, Jinan, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Shijiazhuang, Suzhou, Taiyuan, Wuhan, Wuhu, Xi'an, Xiamen, Zhengzhou
- RecruitingJY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia
- Phase
- N/A
- Started
- 2025-03
- Posted
- Registry
- NCT06890065
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou
- RecruitingA Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Phase
- Phase 3
- Started
- 2025-09
- Posted
- Registry
- NCT06973187
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Dalian, Fuzhou, Harbin, Lanzhou, Luzhou, Nanchang, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Wenzhou, Wuhan, Xi'an, Xining, Xuzhou, Zhengzhou
- RecruitingDZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)
- Phase
- Phase 1/Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07059650
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Linyi, Taiyuan, Wuhan, Xi'an, Zhengzhou
- RecruitingA Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07082686
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Tianjin, Urumqi, Wuhan, Xi'an, Zhengzhou
- RecruitingA Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT07124936
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Kunming, Nanchang, Nanning, Shenyang, Suzhou, Taiyuan, Wuhan, Xi'an, Zhengzhou
- RecruitingA Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07154264
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Guangzhou, Hangzhou, Hefei, Nanchang, Nantong, Shenyang, Wuhan, Yichang, Zhengzhou
- RecruitingOrelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL
- Phase
- Phase 2/Phase 3
- Started
- 2025-10
- Posted
- Registry
- NCT07185373
Age 18 years to 75 years (registered criteria)
Led by Huashan Hospital; 11 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Jinan, Nanchang, Shanghai, Xi'an, Zhengzhou
- RecruitingPA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07188610
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Hangzhou, Hefei, Nanjing, Shanghai, Suzhou, Tianjin, Wuhan, Xuzhou, Zhengzhou
- RecruitingA Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
- Phase
- Phase 2
- Started
- 2025-11
- Posted
- Registry
- NCT07189065
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Wuhan, Xiamen, Xuzhou, Zhengzhou
- RecruitingAn Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
- Phase
- Not given
- Started
- 2025-09
- Posted
- Registry
- NCT07200375
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Changchun, Chengdu, Guangzhou, Harbin, Jinan, Nanchang, Ningbo, Shanghai, Tianjin, Wenzhou, Wuhan, Xi'an, Yantai, Zhengzhou
- RecruitingZanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone Lymphoma
- Phase
- Not given
- Started
- 2025-11
- Posted
- Registry
- NCT07233720
Age not stated (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingA Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas
- Phase
- Phase 1
- Started
- 2024-01
- Posted
- Registry
- NCT06219356
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Hangzhou, Nanchang, Shanghai, Shenyang, Taiyuan, Wuhan, Xiamen, Zhengzhou
- RecruitingA Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Phase
- Phase 1
- Started
- 2024-03
- Posted
- Registry
- NCT06313957
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer Hospital; 1 listed hospital as study siteBeijing, Zhengzhou
- RecruitingA Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06363994
Age 60 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Luoyang, Nanchang, Nanjing, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Zhengzhou
- RecruitingA Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL
- Phase
- Phase 1/Phase 2
- Started
- 2024-03
- Posted
- Registry
- NCT06375733
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanning, Zhengzhou
- RecruitingICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
- Phase
- Phase 2/Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06378138
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Huai'an, Jinan, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Yichang, Zhengzhou, Zunyi
- RecruitingLinperlisib Combined With Chidamide in Patients With PTCL
- Phase
- Phase 1/Phase 2
- Started
- 2024-05
- Posted
- Registry
- NCT06421948
Age 18 years to 80 years (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingEvaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06521255
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang, Shanghai, Suzhou, Tianjin, Urumqi, Wenzhou, Wuhan, Zhengzhou
- RecruitingA Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma
- Phase
- Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06566586
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesChangsha, Guangzhou, Harbin, Hohhot, Lanzhou, Luzhou, Nanchang, Nanning, Shanghai, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Zhengzhou
- RecruitingAxicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma
- Phase
- Phase 4
- Started
- 2024-09
- Posted
- Registry
- NCT06609304
Age 18 years to 70 years (registered criteria)
Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou
- RecruitingA Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor
- Phase
- Phase 1
- Started
- 2024-08
- Posted
- Registry
- NCT06615193
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesHangzhou, Jinan, Nanchang, Suzhou, Tianjin, Xuzhou, Zhengzhou
- RecruitingA Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and Prednisone for the Primary Treatment of Elderly Patients with Newly Diagnosed Diffuse Large B-cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06683885
Age 65 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou
- RecruitingA Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT07234162
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Linyi, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingSelinexor in Combination With MTX+Ritu to Treat R/R CNSL
- Phase
- Phase 1/Phase 2
- Started
- 2023-08
- Posted
- Registry
- NCT05698147
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Fuzhou, Hefei, Shanghai, Zhengzhou
- RecruitingA Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2023-02
- Posted
- Registry
- NCT05800977
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Chongqing, Guangzhou, Hangzhou, Nanchang, Nanjing, Shanghai, Tianjin, Zhengzhou
- RecruitingEfficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
- Phase
- Phase 3
- Started
- 2023-12
- Posted
- Registry
- NCT06082102
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Dalian, Guangzhou, Hangzhou, Nanchang, Qingdao, Shanghai, Shenyang, Wuhan, Xi'an, Yantai, Zhengzhou
- RecruitingA Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
- Phase
- Phase 3
- Started
- 2023-10
- Posted
- Registry
- NCT06084936
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanning, Shanghai, Shenyang, Wenzhou, Zhengzhou
- RecruitingA Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Phase
- Phase 3
- Started
- 2023-12
- Posted
- Registry
- NCT06136559
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Haikou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Taiyuan, Tianjin, Urumqi, Wuhan, Xuzhou, Zhengzhou
- RecruitingJY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia
- Phase
- N/A
- Started
- 2023-09
- Posted
- Registry
- NCT06678282
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou
- RecruitingRelma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell Lymphoma
- Phase
- Phase 2
- Started
- 2023-11
- Posted
- Registry
- NCT06876688
Age 18 years to Not stated (registered criteria)
Led by Ruijin Hospital; 5 listed hospitals as study sitesBeijing, Guangzhou, Shanghai, Wuhan, Zhengzhou
- RecruitingA Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
- Phase
- Phase 2/Phase 3
- Started
- 2022-01
- Posted
- Registry
- NCT05139017
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Luoyang, Nanchang, Shanghai, Wuhan, Zhengzhou
- RecruitingMecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
- Phase
- Phase 2
- Started
- 2022-04
- Posted
- Registry
- NCT05294055
Age 18 years to 65 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 6 listed hospitals as study sitesBeijing, Hefei, Jinan, Tianjin, Zhengzhou
- RecruitingTreatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
- Phase
- Phase 1/Phase 2
- Started
- 2022-05
- Posted
- Registry
- NCT05294731
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Suzhou, Taiyuan, Wenzhou, Wuhan, Zhengzhou
- RecruitingA Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphoma
- Phase
- Not given
- Started
- 2022-08
- Posted
- Registry
- NCT05506410
Age 18 years to 90 years (registered criteria)
Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou
- RecruitingEfficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- Phase
- Phase 2
- Started
- 2021-04
- Posted
- Registry
- NCT04728893
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Tianjin, Wuhan, Xuzhou, Zhengzhou
- RecruitingRituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma
- Phase
- Phase 2
- Started
- 2021-01
- Posted
- Registry
- NCT04737889
Age 18 years to 70 years (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingA Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Phase
- Phase 1/Phase 2
- Started
- 2021-09
- Posted
- Registry
- NCT05006716
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Guangzhou, Shanghai, Tianjin, Wenzhou, Yichang, Zhengzhou
- RecruitingStudy of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
- Phase
- Phase 2
- Started
- 2021-12
- Posted
- Registry
- NCT05147467
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesGuangzhou, Haikou, Hangzhou, Nanchang, Suzhou, Wuhan, Zhengzhou
- RecruitingOrelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma
- Phase
- Phase 2
- Started
- 2021-12
- Posted
- Registry
- NCT05209620
Age 18 years to 75 years (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- RecruitingSafety and Efficacy of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2021-11
- Posted
- Registry
- NCT06021678
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesJinan, Tianjin, Zhengzhou
- RecruitingA Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)
- Phase
- Phase 1
- Started
- 2021-03
- Posted
- Registry
- NCT06189391
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Chengdu, Guangzhou, Jinan, Nanchang, Shanghai, Shijiazhuang, Tianjin, Xiamen, Zhengzhou
- RecruitingStudy to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
- Phase
- Phase 2
- Started
- 2020-01
- Posted
- Registry
- NCT03936153
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Lanzhou, Linyi, Shanghai, Shijiazhuang, Wuhan, Xuzhou, Zhengzhou
- RecruitingEvaluate the Safety and Clinical Activity of HH2853
- Phase
- Phase 1/Phase 2
- Started
- 2020-09
- Posted
- Registry
- NCT04390737
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Zhengzhou
- RecruitingPhase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
- Phase
- Phase 2
- Started
- 2020-10
- Posted
- Registry
- NCT04586478
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Shanghai, Tianjin, Wuhan, Zhengzhou
- RecruitingCorrelation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma
- Phase
- Not given
- Started
- 2019-01
- Posted
- Registry
- NCT04263935
Age not stated (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- Not yet recruitingEfficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Mature B-cell Lymphoma
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07459608
Age 18 years to Not stated (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- Not yet recruitingReal-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma
- Phase
- Not given
- Started
- 2026-03
- Posted
- Registry
- NCT07472621
Age 18 years to Not stated (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- Not yet recruitingA Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide
- Phase
- Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07585747
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 4 listed hospitals as study sitesJinan, Nanchang, Shenzhen, Tianjin, Zhengzhou
- Not yet recruitingLisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted Therapy
- Phase
- Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07684950
Age 18 years to Not stated (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- Not yet recruitingReal-World Study of Bispecific Antibody in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Phase
- Not given
- Started
- 2026-07
- Posted
- Registry
- NCT07695896
Age 18 years to Not stated (registered criteria)
Led by Henan Cancer HospitalZhengzhou
- Not yet recruitingA Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).
- Phase
- Phase 3
- Started
- 2026-10
- Posted
- Registry
- NCT07784101
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Nanjing, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Zhengzhou
- Not yet recruitingOrelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma
- Phase
- Phase 3
- Started
- 2026-10
- Posted
- Registry
- NCT07896590
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 40 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou
- Not yet recruitingEvaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT06845241
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesFuzhou, Guangzhou, Nanchang, Tianjin, Zhengzhou
- Not yet recruitingGlofitamab for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma
- Phase
- Phase 4
- Started
- 2025-05
- Posted
- Registry
- NCT06956092
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou
- Not yet recruitingCD7 CAR-T Combined With Autologous Hematopoietic Stem Cell Transplantation
- Phase
- Phase 1/Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07117305
Age 14 years to 65 years (registered criteria)
Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou
- Not yet recruitingEvaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma
- Phase
- Phase 3
- Started
- 2025-11
- Posted
- Registry
- NCT07187960
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Chongqing, Guiyang, Haikou, Lanzhou, Linyi, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xi'an, Yantai, Zhengzhou
- Not yet recruitingZSDT for the Treatment of R/R Mantle Cell Lymphoma After BTK Inhibitor Failure: a Multi-center Prospective Clinical Trial
- Phase
- Phase 4
- Started
- 2025-12
- Posted
- Registry
- NCT07264894
Age 18 years to 70 years (registered criteria)
Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou
- Not yet recruitingA First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma
- Phase
- Phase 1
- Started
- 2024-04
- Posted
- Registry
- NCT06318884
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Tianjin, Zhengzhou
- Not yet recruitingCAR-T Technology for Recurrent/Refractory Malignant Hematological and Lymphatic Tumors
- Phase
- Phase 1
- Started
- 2024-12
- Posted
- Registry
- NCT06647329
Age 14 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Disease research in Zhengzhou
Each number is papers led on that disease, 2021–2025. “Open” counts open trials the hospital leads. Hospitals A–Z; this is not a ranking.
A blank cell means no papers or trials were found in these records. It does not mean the hospital does not treat that disease.
| Cancer | Blood disorders | Other diseases | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospital | Nasopharyngeal carcinoma | Oesophageal squamous cell carcinoma | Hepatocellular carcinoma | Stomach cancer | Lung cancer | Pancreatic cancer | Breast cancer | Glioma | Hepatoblastoma | Retinoblastoma | Chordoma | Osteosarcoma | Gastrointestinal stromal tumour | Neuroblastoma | Ewing sarcoma | Multiple myeloma | B-cell acute lymphoblastic leukaemia | Aplastic anaemia | Haemophagocytic lymphohistiocytosis | Lymphoma | Beta thalassaemia | Haemophilia A | Atypical haemolytic uraemic syndrome | Thrombotic thrombocytopenic purpura | Fanconi anaemia | Neuromyelitis optica spectrum disorder | IgG4-related disease | Myasthenia gravis | Moyamoya disease | Wilson disease | Biliary atresia | Coronary heart disease | Congenital heart disease | Scoliosis | Anti-NMDA receptor encephalitis | Takayasu arteritis | Hepatic echinococcosis | Idiopathic pulmonary fibrosis | Lymphangioleiomyomatosis | Amyotrophic lateral sclerosis | Spinal muscular atrophy | Fabry disease | Pompe disease | Duchenne muscular dystrophy | Behçet disease | Alport syndrome | IgA nephropathy | Gaucher disease | Niemann–Pick disease type C | Osteogenesis imperfecta | Primary biliary cholangitis | Primary sclerosing cholangitis | Congenital diaphragmatic hernia | Hirschsprung disease | Inherited epidermolysis bullosa | Hereditary angioedema | Familial adenomatous polyposis | Leber hereditary optic neuropathy | Majeed syndrome | NGLY1 deficiency | ISG15 deficiency | Shortlist |
| Affiliated Children's Hospital of Zhengzhou University河南省儿童医院郑州儿童医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Central China Fuwai Hospital | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 11 open | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Children's Hospital, Zhengzhou University河南省儿童医院(郑州儿童医院) | none | none | none | none | none | none | none | none | none | 1 | none | 2 | 0 | 9 | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | 5 | none | 0 | none | none | 0 | none | none | none | 0 | none | 1 | 0 | 0 | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | |
| Fifth Affiliated Hospital of Zhengzhou University郑州大学第五附属医院 | none | none | none | 11 | none | none | none | 12 | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| First Affiliated Hospital of Henan University of Chinese Medicine河南中医药大学第一附属医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | 0 | none | none | 14 | none | none | none | none | none | none | none | none | 3 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| First Affiliated Hospital of Zhengzhou University郑州大学第一附属医院 | 15 | 796 open | 1692 open | 1055 open | 2042 open | 391 open | 97 | 826 open | 2 | 5 | 0 | 34 | 8 | 15 | 3 | 15 | 11 open | 9 | 3 | 857 open | 0 | 3 | none | 1 | none | 11 | none | 4 | 10 | 1 | none | 361 open | 9 | 12 | 9 | 0 | 1 | 12 | 0 | 5 | 0 | 0 | 0 | 6 | 9 | 0 | 35 | none | none | 0 | 2 | none | none | 0 | none | none | none | 2 | none | none | none | |
| Fuwai Central China Cardiovascular Hospital阜外华中心血管病医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Henan Cancer Hospital河南省肿瘤医院 | 1 | 414 open | 341 open | 764 open | 929 open | 10 | 7727 open | 10 | none | 0 | none | 19 | 1 | 1 | 0 | 18 | 0 | 4 | none | 279 open | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | |
| Henan Provincial Chest Hospital河南省胸科医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Henan Provincial People's Hospital河南省人民医院 | 3 | 20 | 30 | 25 | 66 | 13 | 39 | 566 open | none | 2 | 0 | 7 | 0 | 3 | 0 | 5 | none | none | none | 13 | none | 2 | none | 1 | 1 | 2 | none | 2 | 5 | none | none | 26 | 14 | 0 | 2 | 0 | none | 5 | none | 1 | none | none | none | 1 | none | none | 1 | none | none | 0 | 0 | 0 | none | none | 2 | 0 | none | 3 | none | none | none | |
| Nanozyme Medical Center郑州大学基础医学院纳米酶医学中心 | none | 3 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Second Affiliated Hospital of Henan University of Traditional Chinese Medicine河南省中医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | 2 | 0 | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Second Affiliated Hospital of Zhengzhou University郑州大学第二附属医院 | none | 7 | none | none | none | none | none | 9 | none | none | 2 | 3 | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 3 | none | none | none | 1 | 5 | none | 1 | none | none | none | none | 0 | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | |
| Third Affiliated Hospital of Henan University of Chinese Medicine河南中医药大学第三附属医院 | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Third Affiliated Hospital of Zhengzhou University郑州大学第三附属医院 | none | none | none | none | none | none | none | none | 1 | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 3 | none | none | none | none | none | none | none | 0 | none | none | 1 | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | |
| Zhengzhou Central Hospital郑州市中心医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Zhengzhou Central Hospital, Zhengzhou University郑州大学附属郑州中心医院 | 2 | 4 | none | none | none | none | none | none | none | none | none | 4 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Zhengzhou First People's Hospital郑州市第一人民医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Zhengzhou Orthopedic Hospital郑州市骨科医院 | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Zhengzhou People's Hospital郑州人民医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | |
| Zhengzhou Second Hospital | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
Column labels are short names. Choose one to open that disease in Zhengzhou.
- Nasopharyngeal carcinoma 15
- Oesophageal squamous cell carcinoma 796 open
- Hepatocellular carcinoma 1692 open
- Stomach cancer 1055 open
- Lung cancer 2042 open
- Pancreatic cancer 391 open
- Breast cancer 97
- Glioma 826 open
- Hepatoblastoma 2
- Retinoblastoma 5
- Chordoma 0
- Osteosarcoma 34
- Gastrointestinal stromal tumour 8
- Neuroblastoma 15
- Ewing sarcoma 3
- Multiple myeloma 15
- B-cell acute lymphoblastic leukaemia 11 open
- Aplastic anaemia 9
- Haemophagocytic lymphohistiocytosis 3
- Lymphoma 857 open
- Beta thalassaemia 0
- Haemophilia A 3
- Thrombotic thrombocytopenic purpura 1
- Neuromyelitis optica spectrum disorder 11
- Myasthenia gravis 4
- Moyamoya disease 10
- Wilson disease 1
- Coronary heart disease 361 open
- Congenital heart disease 9
- Scoliosis 12
- Anti-NMDA receptor encephalitis 9
- Takayasu arteritis 0
- Hepatic echinococcosis 1
- Idiopathic pulmonary fibrosis 12
- Lymphangioleiomyomatosis 0
- Amyotrophic lateral sclerosis 5
- Spinal muscular atrophy 0
- Fabry disease 0
- Pompe disease 0
- Duchenne muscular dystrophy 6
- Behçet disease 9
- Alport syndrome 0
- IgA nephropathy 35
- Osteogenesis imperfecta 0
- Primary biliary cholangitis 2
- Hirschsprung disease 0
- Leber hereditary optic neuropathy 2
- Nasopharyngeal carcinoma 1
- Oesophageal squamous cell carcinoma 414 open
- Hepatocellular carcinoma 341 open
- Stomach cancer 764 open
- Lung cancer 929 open
- Pancreatic cancer 10
- Breast cancer 7727 open
- Glioma 10
- Retinoblastoma 0
- Osteosarcoma 19
- Gastrointestinal stromal tumour 1
- Neuroblastoma 1
- Ewing sarcoma 0
- Multiple myeloma 18
- B-cell acute lymphoblastic leukaemia 0
- Aplastic anaemia 4
- Lymphoma 279 open
- Haemophilia A 1
- Familial adenomatous polyposis 1
- Nasopharyngeal carcinoma 3
- Oesophageal squamous cell carcinoma 20
- Hepatocellular carcinoma 30
- Stomach cancer 25
- Lung cancer 66
- Pancreatic cancer 13
- Breast cancer 39
- Glioma 566 open
- Retinoblastoma 2
- Chordoma 0
- Osteosarcoma 7
- Gastrointestinal stromal tumour 0
- Neuroblastoma 3
- Ewing sarcoma 0
- Multiple myeloma 5
- Lymphoma 13
- Haemophilia A 2
- Thrombotic thrombocytopenic purpura 1
- Fanconi anaemia 1
- Neuromyelitis optica spectrum disorder 2
- Myasthenia gravis 2
- Moyamoya disease 5
- Coronary heart disease 26
- Congenital heart disease 14
- Scoliosis 0
- Anti-NMDA receptor encephalitis 2
- Takayasu arteritis 0
- Idiopathic pulmonary fibrosis 5
- Amyotrophic lateral sclerosis 1
- Duchenne muscular dystrophy 1
- IgA nephropathy 1
- Osteogenesis imperfecta 0
- Primary biliary cholangitis 0
- Primary sclerosing cholangitis 0
- Inherited epidermolysis bullosa 2
- Hereditary angioedema 0
- Leber hereditary optic neuropathy 3
Other cities nearby
Straight-line distance from the city centre; counts are hospitals listed for lymphoma.
Counts are listed hospitals only, not every hospital in each city.
Where these numbers come from
Papers
English-language PubMed papers, 2021–2025, where the first or last author lists the hospital first. Definitions
Trials
ClinicalTrials.gov records with the hospital as lead sponsor or site, as of 8 Nov 2026. Search Zhengzhou on ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.